share_log

Candel Therapeutics Analyst Ratings

Benzinga Analyst Ratings ·  Dec 7, 2022 20:56
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
12/07/2022 379.04% Credit Suisse $10 → $8 Maintains Outperform
12/02/2022 558.68% HC Wainwright & Co. → $11 Initiates Coverage On → Buy
03/31/2022 618.56% BMO Capital $18 → $12 Maintains Outperform
11/19/2021 977.84% BMO Capital → $18 Initiates Coverage On → Outperform
08/23/2021 438.92% UBS → $9 Initiates Coverage On → Buy
08/23/2021 1217.37% Jefferies → $22 Initiates Coverage On → Buy
08/23/2021 798.2% Credit Suisse → $15 Initiates Coverage On → Outperform

What is the target price for Candel Therapeutics (CADL)?

The latest price target for Candel Therapeutics (NASDAQ: CADL) was reported by Credit Suisse on December 7, 2022. The analyst firm set a price target for $8.00 expecting CADL to rise to within 12 months (a possible 379.04% upside). 3 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Candel Therapeutics (CADL)?

The latest analyst rating for Candel Therapeutics (NASDAQ: CADL) was provided by Credit Suisse, and Candel Therapeutics maintained their outperform rating.

When is the next analyst rating going to be posted or updated for Candel Therapeutics (CADL)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Candel Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Candel Therapeutics was filed on December 7, 2022 so you should expect the next rating to be made available sometime around December 7, 2023.

Is the Analyst Rating Candel Therapeutics (CADL) correct?

While ratings are subjective and will change, the latest Candel Therapeutics (CADL) rating was a maintained with a price target of $10.00 to $8.00. The current price Candel Therapeutics (CADL) is trading at is $1.67, which is out of the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment